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Yunchuan Ding,1 Marcello Rotta,1 Scott S. Graves,1,2 Barry E. Storer,1,3 Laura J. Peterson,1
George E. Sale,1,4 Reza Forough,1 Eustacia Zellmer,1 George E. Georges,1,2
Brenda M. Sandmaier,1,2 Christian S. Kuhr,1,5 Rainer Storb1,2Exposure to accidental or deliberate radiation poses a threat to public health, proving lethal at higher doses
in large part because of deleterious effects on marrow. In those cases, allogeneic hematopoietic cell trans-
plantation (HCT) might be required to restore marrow function. Most radiation accident victims will have
HLA-haploidentical relatives who could serve as HCT donors. Here, we assessed in a canine HCT model
the total body irradiation (TBI) doses after which transplants might be required and successful engraftment
would be possible. In an attempt at mimicking the logistical problems likely to exist after radiation accidents,
4-, 8- or 10-day intervals were placed between TBI and HCT. To keep the experimental readout simple, no
graft-versus-host disease (GVHD) prevention was administered. All dogs transplanted after a 4-day delay fol-
lowing 700 or 920 cGy TBI successfully engrafted, whereas virtually all those given 450 or 600 cGy rejected
their grafts. Transplant delays of 8 and 10 days following 920 cGy TBI also resulted in successful engraftment
in most dogs, whereas a delay of 8 days after 700 cGy resulted in virtually uniform graft failure. The time
courses of acute GVHD (aGVHD) and rates of granulocyte recovery in engrafting dogs were comparable
among dogs regardless of the lengths of delay. In other studies, we showed that most dogs not given
HCT survived 700 cGy TBI with intensive supportive care, whereas those given 800 cGy TBI and higher
died with marrow aplasia. Thus, DLA-haploidentical HCT was successful even when carried out 4, 8, or
10 days after TBI at or above radiation exposures where dogs survived with intensive care alone.
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Radiation poses a significant threat to public health
through either accidental or deliberate exposures,
proving lethal at higher doses in large part because of
its deleterious effects on hematopoiesis. In those cases,
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6/j.bbmt.2009.06.004might be required to restore marrow function. We
previously showed that marrow grafts from DLA-
identical canine littermates were beneficial in the
setting of total body exposures to g-radiation ranging
from 450-1150 cGy, with most dogs surviving either
with sustained allogeneic engraftment or eventual
autologous marrow recovery after cellular support
provided by transient allografts [1,2].
Realistically, most potential radiation accident
victims will not have HLA-identical siblings who
could serve as HCT donors, and there will not be
sufficient time to search for suitably HLA-matched
unrelated donors. However, it is safe to assume that
virtually everyone will have HLA-haploidentical
family members among parents, siblings, or children.
Therefore, the current study evaluated in a canine
model in which after total body irradiation (TBI) expo-
sures DLA-haploidentical HCT might be feasible and
potentially useful. To mimic the logistical problems
likely to exist after radiation accidents, 4-, 8-, and
10-day intervals were placed between TBI and HCT.
To have a clear-cut study end point, no attempts
were made to prevent graft-versus-host disease
Biol Blood Marrow Transplant 15:1244-1250, 2009 1245Delaying DLA- Haploidentical HCTafter TBI(GVHD), which therefore served as 1 of the readouts
for successful allogeneic hematopoietic engraftment.MATERIALS AND METHODS
Dogs
Litters of random-bred dogs were either raised at
the Fred Hutchinson Cancer Research Center
(FHCRC) or purchased from commercial Class A ven-
dors licensed by the U.S. Department of Agriculture.
The dogs weighed from 7.0 to 13.8 (median, 10.8) kg
and were between 10 and 27 (median, 16.3) months
old. All dogs were enrolled in a veterinary preventive
medicine program that included routine anthelmintics
and a standard immunization series [3]. The study was
approved by the Institutional Animal Care and Use
Committee at the FHCRC, which has been fully
accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care.
Littermate donor and recipient pairs were selected
on the basis of complete family studies showing
haplo-identity for highly polymorphic major histo-
compatibility complex (MHC)-associated class I and
II microsatellite markers [4] and for DLA-DRB1
alleles determined by direct sequencing [5].TBI AND HCT
TBI was delivered as a single dose at a rate of
7 cGy/min from a 4 MEV and, more recently, a 6
MEV linear accelerator (CLINAC 4/80 and CLINAC
600 C/D, respectively, Varian Associates, Palo Alto,
CA). In 1 arm of the study, recipient dogs were given
920, 700, 600, or 450 cGy TBI 4 days before HCT
(Table 1). In another arm, recipient dogs were given
920 or 700 cGy TBI 8 days before HCT. In a third
study arm, recipients were given 920 cGy TBI 10
days before HCT. HCT consisted of i.v. infusions of
marrow containing 1.5 to 7.5 (median, 3.8) 108 nu-
cleated cells per kilogram recipient body weight and
1.1 to 7.1 (median, 2.4) 108 peripheral blood buffy
coat cells per kilogram body weight. The day of
HCT was designated day 0. For comparison, previ-
ously published data on dogs given either 450 or
920 cGy TBI immediately preceding hematopoietic
cell grafts from DLA-haploidentical littermates were
also summarized (Table 2). For ease of interpretation
of results, recipients were not given postgrafting im-
munosuppression for prevention of GVHD. Support-
ive care included prophylaxis with the oral antibiotic
enrofloxacin from the day of TBI until the end of the
study. Broader antibiotic coverage was administered
when neutrophil counts declined to below 0.3 106/
mL or fever developed. i.v. fluids were administered
when an excess of 8% dehydration occurred. Irradiatedblood transfusions were given either when platelet
counts declined below 0.5106/mL or when petechiae
and ecchymoses of skin and mucous membranes were
observed.
Engraftment/Chimerism
Hematopoietic engraftment was assessed by
increases in granulocyte and platelet counts following
postirradiation nadirs, marrow histology from autopsy
specimens, documentation of donor-type hematopoie-
sis in peripheral blood andmarrow by variable number
tandem repeat (VNTR) polymorphisms [6,7], and
clinical and histologic evidence of GVHD.
Statistical Analysis
Logistic regressionwas used to develop a predictive
model for the probability of engraftment as a function
of the TBI dose and the delay between TBI and HCT.RESULTS
Table 1 summarizes the data for 7 current groups
of dogs, and Table 2 shows results in 3 historical
groups of dogs. Dogs in groups 1-4 were given TBI
4 days before HCT. All 5 dogs given 920 cGy (group
1) and all 5 given 700 cGy (group 2) TBI showed
prompt allogeneic engraftment. Sustained increases
in granulocyte counts were seen after the TBI nadirs,
which occurred between 4 and 5 days after HCT, re-
spectively, with counts rising to an average of
1 106/mL 8 days after HCT. All 10 dogs developed
clinical and histologic evidence of acute GVHD
(aGVHD) and were euthanized because of GVHD
on a median of 15 days after TBI, and 11 days after
HCT, respectively. Complete donor-type hematopoi-
esis was documented by VNTR assays of peripheral
blood and bone marrow in all 10 dogs. In contrast, 3
of 5 dogs given 600 cGy (Group 3) rejected their allo-
grafts and survived with autologous marrow recovery.
One dog (G817) remained pancytopenic, showed pre-
dominantly host, but also some donor, hematopoietic
cells, and was euthanized on day 40 after HCT because
of infection. One dog (G801) had sustained engraft-
ment of donor cells and was euthanized 10 days after
HCT because of severe GVHD. All 4 dogs given
450 cGy (Group 4), rejected their allografts and 3 of
4 showed autologous recovery. Two of the 3 were eu-
thanized at the end of study and 1 was euthanized be-
cause of septicemia. The fourth dog (G650) rejected
the allograft and was eventually euthanized on day 49
because of persisting low blood counts.
All 4 dogs given HCT 8 days after 920 TBI
(Group 5) also had sustained engraftment of donor
cells and developed both histologic and clinical signs
of GVHD. Granulocyte recoveries were seen in 3 of
4 dogs on average 7 days after HCT (15 days after
Table 1. Hematopoietic Cell Grafts from DLA-haploidentical Littermates Administered 4, 8, or 10 Days after TBI
Group
TBI
Dose (cGy)
HCT
Delay (Days)
Recipient
No.
Granulocyte
Recovery*
GVHD
Sustained
Allograft†
Autologous
Marrow
Recovery
Marrow
Cellularity‡
at Autopsy (%)
Origin of
Hematopoietic
Cells
Survival (Days) after
Causes of
Death§Histological Clinical
Day of Onset
after HCT TBI HCT
1 920 4 G674 Yes S,G,L S,G,L 10 Yes No 15 Donor 16 12 ET1, GVHD
G658 Yes S,G,L S,G,L 8 Yes No 20 Donor 14 10 ET1, GVHD
G615 Yes S,G,L SL 11 Yes No 25 Donor 18 14 ET1, GVHD
G684 Yes S,G,L S,L 8 Yes No 65 Donor 15 11 ET1, GVHD
G520 Yes S,G,L S,G,L 10 Yes No 25 Donor 15 11 ET1, GVHD
2 700 4 G535 Yes S,G,L S,L 10 Yes No 35 Donor 15 11 ET1, GVHD
G679 Yes S,G,L S,L 15 Yes No 52 Donor 22 18 ET1,GVHD
G816 Yes S,G,L S,L 8 Yes No 65 Donor 15 11 ET1,GVHD
G687 Yes S,G,L S,L 9 Yes No 50 Donor 15 11 ET1,GVHD
G818 Yes S,G,L S,L 8 Yes No 25 Donor 15 11 ET1,GVHD
3 600 4 G793 Yes No No – No Yes 100 Host 83 79 ET2
G817 No No No – No No 2 Host/ Donor 44 40 ET1, Aplasia
G805 Yes No No – No Yes 45 Host 27 23 ET2
G801 Yes S,G,L S, L 9 Yes No 35 Donor 14 10 ET1,GVHD
G304 Yes No No – No Yes 7.5 Host 48 44 ET2
4 450 4 G683 Yes No No – No Yes NE Host 39 35 ET2
G650 Yes No No – No Yes 75 Host 53 49 ET1, Anemia
G681 Yes No No – No Yes 75 Host 54 50 ET2
G578 No No No – No No 0 Host 30 26 Septicemia
5 920 8 G466 Yes S,G,L S,G,L 8 Yes No 50 Donor 17 9 ET1,GVHD
G762 Yes S,G.L S,G,L 8 Yes No 50 Donor 17 9 ET1,GVHD
G757 Yes S,G,L S,G,L 9 Yes No 25 Donor 18 10 ET1,GVHD
G976 No S S,L 7 Yes No <5 Donor 15 7 Septicemia, ET1,GVHD
6 700 8 H049 No S,G,L S,G.L 11 No No 15 Host 19 11 ET1, Pancytopenia
H064 No S,G,L S,L 6 Yes No 15 Donor 16 8 GVHD
H123 Yes No No – No Yes 25 Host 43 35 ET2
H092 No No No – No No 15 Host 34 26 ET1, Septicemia
H065 No No No – No No 5 Host 21 13 ET1, Septicemia
7 920 10 G991 No No No – No No <5 Host 25 15 ET1
H013 No S,G,L S,G,L 7 Yes No 15 Donor 18 8 ET1, Septicemia
H031 No S,G,L S,G,L 7 Yes No 15 Donor 18 8 ET1,GVHD
G601 Yes S,G,L S,G,L 9 Yes No 50 Donor 18 10 ET1,GVHD
H112 No S,G,L S,G,L 8 No No <5 Host 20 10 ET1,Septicemia
ET1 indicates euthanized, poor condition; ET2, euthanized, end of study; G, gut L, liver; NE, not evaluated; S, skin;
*Increases of peripheral granulocyte counts to $1 10 6/mL after postirradiation nadirs.
†Sustained engraftment was demonstrated by persistence of donor cells in peripheral blood and donor-type hematopoiesis in bone marrow when assayed for variable number tandem repeat (VNTR) polymorphisms.
‡Cell fat ratio.
§Dogs were euthanized at the end of study because of poor clinical condition (ET1, GVHD), or when autologous recovery of host hematopoiesis had occurred (ET2).
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Table 2. Hematopoietic Cell Grafts from DLA-haploidentical Littermates Administered within Hours (Day 0) of TBI: Historical
Data
Group
TBI Dose
(cGy)
Source of
Cells
No. of Dogs Survival (Days)
Causes of Death ReferenceStudied Sustained Grafts Acute GVHD Range Median
8 920 Marrow/BC 6 6 6 8-13 10.5 ET1; GVHD [10]
9 920 GPBMC ± SCF 9 9 9 7-12 7 ET1; GVHD [8]
10 450 GPBMC 6 1 1 13-80 21 ET1; GVHD (n5 1) ET1 (n5 2)
ET2 (n5 2) Pneumonia (n5 1)
[9]
BC indicates buffy coat; ET1, euthanized, poor condition; ET2, euthanized, end of study; GPBMC, G-CSF-mobilized peripheral blood mononuclear cells;
SCF, stem cell factor.
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GVHD. In contrast, only 1 of 5 dogs given HCT 8
days after 700 cGy TBI (group 6) had sustained en-
graftment and GVHD, whereas 4 rejected; 2 of the lat-
ter 4 were euthanized because of sepsis, 1(H123) was
euthanized after complete autologous recovery, and 1
(H049) was euthanized because of infection from pan-
cytopenia and with clinical evidence of GVHD, even
though residual hematopoiesis was entirely of host or-
igin. Three of 5 dogs given 920 cGy TBI and HCT af-
ter a delay of 10 days (group 7) had sustained
engraftment of donor cells, developed GVHD, and
were euthanized. Their neutrophil changes are shown
in Figure 1. Two dogs rejected the allografts, remained
pancytopenic, and were euthanized because of septice-
mia/poor clinical condition.
For comparison, Table 2 summarizes previous
data in dogs given either 450 or 920 cGy TBI immedi-
ately before infusion of marrow/buffy coat cells or
canine stem cell factor (SCF) and/or canine granulo-
cyte-colony stimulating factor (G-CSF)-mobilized
peripheral blood stem cells (PBSCs), from DLA-
haploidentical littermates [8-10]. Historically,
G-CSF 6 SCF mobilized blood cells have shown the
same engraftment potential as the combination of
marrow and buffy coat cells used in the present study.
All 15 dogs treated with 920 cGy and immediate HCT
(groups 8 and 9) had sustained donor engraftment and1
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Figure 1. Granulocyte changes in dogs given 920 cGy TBI and
transplanted with marrow and buffy coat cells from DLA-haploidentical
littermates after 0-, 4-, 8-, and 10-day delays. The median granulocyte
counts for each group were determined and normalized to day 0, the
day of marrow and buffy coat infusions.were euthanized because of GVHD; their survivals
were comparable to those of dogs given HCT after
4- to 10-day delays. Only 1 of 6 dogs given 450 cGy
TBI on the day of HCT (group 9) had sustained en-
graftment and was euthanized on day 13 because of
GVHD, whereas 5 rejected their grafts and showed au-
tologous marrow recovery. Four of the latter were eu-
thanized at the end of study, whereas 1 died of
pneumonia on day 19. This outcome was comparable
to that in dogs given 600 cGy TBI 4 days before HCT.
Peripheral blood granulocyte changes among dogs
given 920 cGy TBI 4, 8, and 10 days before HCT
(groups 1, 5, and 7) were normalized with respect to
day ofHCT (Figure 1) . The times to nadir and recovery
of granulocytes were similar for dogs in the 3 groups.
The immediate but transient neutrophil rises seen after
delayedHCTwere likely the result of transient produc-
tion from committed granulocyte precursors contained
in the marrow grafts. For comparison, Figure 1 also
shows granulocyte changes in 9 dogs given HCT on
day 0; note that, although the nadir is obviously delayed
and higher, the recovery curve matches those in the
other 3 groups of dogs. Full recovery of lymphocyte
counts was precluded by the onset of GVHD and the
need for euthanizing the dogs with the possible excep-
tion of the 8-day delay group in which the median lym-
phocyte counts increased to 800 cells/mL from less than
100 cells/mL 10 days after HCT (data not shown).
A logistic regressionmodelwasfit to thedata fromall
of the groups except group 8 to develop a predictive
model for the probability of engraftment as a function
of TBI dose and the delay between TBI and HCT.
The estimated probability of engraftment (P) from this
model was expressed as P5 exp(X)/(11 exp(X)), where
X5213.11 2.68TBI dose (Gray) –1.03Delay
(days). Model predictions and observed data are shown
in Figure 2. Consistent with radiobiologic principles,
the TBI doses required for uniform engraftment
increased in direct relation to the increases in time inter-
vals between TBI and HCT.DISCUSSION
Tocreate a preclinical setting thatmimicked the lo-
gistical problems likely to exist after radiation
Figure 2. Estimated probability of engraftment as a function of TBI
dose for delays of 0, 4, 8, and 10 days. The lines were the estimated
percentages derived from the logistic regression model; points were
the observed percentages from groups 1-7 and 9 in Table 1.
1248 Biol Blood Marrow Transplant 15:1244-1250, 2009Y. Ding et al.accidents, we focused on HCT donors among the im-
mediate family that shared at least 1 MHC-haplotype
with the accident victims, in this case, surrogates in
the form of DLA-haploidentical littermates. In the
case of human patients, MHC-haploidentical donors
would include both parents, all children, and half of
the siblings. MHC-haplodisparity raised 2 major
issues: engraftment without rejection and, once the
engraftment barrier had been crossed, GVHD.
With respect to engraftment, TBI is not only mye-
loablative (MA) but also immunosuppressive. Thus, at
high TBI doses, host resistance to MHC-haploidenti-
cal hematopoietic grafts is weakened to a point where
the immunologic balance is shifted in favor of the
grafts. Typically, TBI delivered as a single dose of
920 cGy was sufficient for uniform, sustained engraft-
ment in dogs given MHC-haploidentical hematopoi-
etic cell grafts within 24 hours of TBI when the
immunosuppressive effect of radiation was at its peak
[11,12]. Early studies on the effects of TBI on immune
responses had shown regeneration of immunity as time
elapsed after irradiation exposure [13-17]. When de-
signing the current studies, we reasoned that, at the
very earliest, an MHC-haploidentical donor might
be identified and ready to deliver a hematopoietic
cell graft 4 days after accidental radiation exposure of
the recipient, although 4 days might be unrealistically
short for mobilizing appropriate emergency care
considering the recent experience after hurricane
Katrina. Therefore, we also explored HCT 8 and 10
days after TBI. Encouragingly, the study showed
virtually uniform engraftment of DLA-haploidentical
hematopoietic cells transplanted 4 and 8 days after
920 cGy, the highest TBI dose studied, whereas only
3 of 5 dogs transplanted after a 10-day delay engrafted,
suggesting the time limits for successful engraftment
had been approached. The rates of neutrophil recovery
in the 3 groups of dogs were not distinguishable fromeach other, or from those of ‘‘historical’’ control dogs
given HCT on the day of TBI, when ‘‘normalized’’
for day of transplantation, suggesting normal function
even when grafts were infused 10 days after TBI.
Lowering the TBI dose to 700 cGy allowed for uni-
formly sustained grafts after a 4-day delay; however,
all but 1 of the dogs rejected their grafts when infused
after an 8-day delay. This finding was consistent with
the notion of immunologic recovery of host cells
over time, as shown by the early radiobiologic studies
[13-17]. As we lowered the TBI dose to 600 cGy and
450 cGy, respectively, virtually all DLA-haploidenti-
cal grafts infused after 4 days were rejected, indicating
inadequate host immunosuppression at these doses.
The 4-day minimum interval between radiation
exposure and HCT precluded use of G-CSF-mobilized
peripheral blood mononuclear cells (PBMC) for which
at least 5 days were required to transfer sufficient
numbers of CD341 progenitor/stem cells from mar-
row into blood [8]. Conversely, using marrow alone
led to very high incidences (60%–90%) of graft rejec-
tion in MHC-mismatched dogs, even when infused
immediately after 920 cGy TBI [12,18]. This prob-
lem has been attributed to destruction of marrow
grafts by relatively radioresistant host natural killer
(NK) cells [19]. Given these restrictions, we added
donor buffy coat cells to the marrow inoculum which,
as shown already years ago [11,12], helped overcome
the host NK cell barrier, presumably through a shift
in the immunologic balance toward the donor by
high numbers of infused lymphocytes [12,20].
A number of studies have evaluated the effects of
varying time intervals between TBI and infusion of
hematopoietic grafts. Virtually all studies were done
in inbred rodents. One of the first, published in 1961
[21], found that 30-day survivals after syngeneic grafts
declined from 92% to 50% as the time interval was
increased from 1 to 8 days. Vos et al. [22], grafting
rat marrow into mice, also reported declining 30-day
survivals from 85% to 25% when increasing the time
interval from 1 to 4 days. Fiala et al. [23] saw best
results when murine grafts were carried out 1 day after
TBI and worse outcomes after 4 days. In contrast,
more recent studies of marrow transplantation in
inbred H2-mismatched mice suggested that a 4-day
delay compared to no delay improved engraftment at
doses of 500 and 600 cGy, but not at 700 cGy TBI
[24]. The authors explained this counterintuitive find-
ing by a significant increase in the inflammatory cyto-
kine IL-6 directly after TBI which, somehow,
impaired engraftment early after TBI and which
declined over time.
Another study in H2-incompatible mice showed
both a dramatic reduction in GVHD and improve-
ment in survival from 0% to 60% when the time
interval from TBI to transplantation was increased
from 0 to 4 days [25]. The uniformly poor outcome
Biol Blood Marrow Transplant 15:1244-1250, 2009 1249Delaying DLA- Haploidentical HCTafter TBIof transplantation on day 0 was attributed to cytokine
release (‘‘cytokine storm’’) induced by TBI [26-28]
which ‘‘caused or aggravated host tissue damage and
modulated MHC antigen expression,’’ thereby leading
to lethal GVHD. The authors postulated that by
delaying the transplant by 4 days, the cytokine reaction
cycle would be interrupted, thereby reducing tissue
damage and GVHD incidence and mortality.
In contrast to the observations inmice, current and
past results in randombred dogs failed to show attenu-
ation of GVHD with increasing time interval between
TBI and HCT. Regardless of whether grafts were in-
fused on days 0, 4, 8, or even 10 after 920 cGy TBI,
all dogs promptly developed GVHD, which was fatal
within 8 to 14 days of HCT. Extending the reasoning
used to explain the murine study results [24,25], we
would expect a TBI-induced ‘‘cytokine storm’’ to
have subsided by days 4, 8, and 10 when current grafts
were infused. Yet, aGVHD occurred as fast and was as
severe in dogs transplanted 4 to 10 days after TBI as in
those given their hematopoietic grafts within hours of
TBI. Clearly, in this large, randombred animal model,
the degree of histoincompatibility between donors and
recipients was the major determinant for the tempo of
immunologic reactions leading to GVHD, regardless
of the timing of transplantation after TBI.
How to explain the profound effect of the ‘‘cyto-
kine storm’’ on outcomes of murine HCT and the
apparent lack of effect in the canine model? Is it possi-
ble that inbred mice, kept in relatively pathogen-free
barrier facilities, were especially responsive to radia-
tion insults in generating cytokines, whereas dogs
(and also human patients) have been continuously
exposed to bacterial, fungal, and viral antigens, with
the result that those exposures overshadowed the effect
of the additional TBI exposure?
As already indicated, the current study did not
attempt to prevent GVHD. Earlier studies had shown
that antimetabolites, such as methotrexate (MTX) or
mycophenolate mofetil (MMF), given either alone or
combined with calcineurin inhibitors, could amelio-
rate or even prevent GVHD [29-32]. Yet, other studies
in dogs conditioned with 920 cGy TBI showed facili-
tation of engraftment of DLA-nonidentical marrow
with a short course of postgraftingMTX [33], presum-
ably by hindering the proliferation of radioresistant
host NK cells [19]. Similarly, combining MMF with
a calcineurin inhibitor facilitated engraftment of
DLA-identical marrow after suboptimal TBI doses
[34]. Conceivably, therefore, the use of postgrafting
immunosuppression in the current model might not
only extend the time threshold for uniform engraft-
ment, say, after 920 cGy TBI beyond 8 days, but,
moreover, allay GVHD and assure long-term survival.
Current study results have to be seen in the context
of what can be achieved with state-of-the-art supportive
care without HCT in this canine model. We reportedpreviously uniform endogenous recovery and survival
in dogs given 200 cGy TBI without marrow ‘‘rescue,’’
whereas most dogs given 400 cGy TBI died as a conse-
quence of pancytopenia [35,36]. Most recently, perhaps
owing to more advanced antibiotics and more intensive
fluid and electrolyte support,most dogs exposed toup to
700 cGy TBI survived, whereas those given 800 cGy
TBI eventually were euthanized because of complica-
tions frompancytopenia (G.Georges et al., unpublished
observations). Taken together, results of the current
study and those in dogs not given hematopoietic grafts
suggested that optimal supportive care could save indi-
viduals exposed up to a maximum of 700 cGy TBI,
whereas DLA-haploidentical HCT were successful at
doses of 700 cGy or higher. It must be remembered,
however, that thesedataweregeneratedusinga relatively
low dose rate of 7 cGy/min.We know fromearlier stud-
ies in dogs that higher dose rates generated different
toxicity profiles on the hematopoietic system, the gut,
and slow-responding tissues [36,37]. Dose rates experi-
enced in radiation accidents might vary widely, and
higher dose rates should be evaluated in the current
preclinical model.
In conclusion, most DLA-haploidentical HCT
was successful even after 4-, 8- and 10-day intervals
from TBI doses at and above levels where dogs could
be saved by intensive supportive care.ACKNOWLEDGMENTS
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